Infectious Disease Research Institute (IDRI)

56 articles with Infectious Disease Research Institute (IDRI)

• Amyris Completes First Major License For Leading RNA Vaccine Advancing Technology To Human Trials

  7/1/2021

   Amyris, Inc. today announced that it has signed an exclusive license with Nant Africa , LLC relating to the development and use of the RNA Covid vaccine Amyris devloped in coordination with the Infectious Disease Research Institute.

• 

  Research Roundup: Neuronal Cell Death in Alzheimer’s and More

  5/14/2021

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

• New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential

  5/10/2021

  The Infectious Disease Research Institute, Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2, as well as other coronaviruses.

• 

  New COVID-19 Vaccine on the Block Displays Multi-Variant Potential

  5/10/2021

  The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M are working together on a potential vaccine that might protect individuals against multiple variants of SARS-CoV-2.

• Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine

  10/22/2020

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute

• Amyris and The Infectious Disease Research Institute Partner to Advance Novel RNA Vaccine Platform Beginning With COVID-19 Application

  7/27/2020

   Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets and IDRI (Infectious Disease Research Institute) today announce the signing of a binding term sheet for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program. The program combines IDRI's expertise in combating i

• Infectious Disease Research Institute (IDRI) Release: Promising New Leprosy Vaccine Moves Into Human Trials

  10/12/2017

• Infectious Disease Research Institute (IDRI) To Continue Development Of Inhalable TB Drug Candidate

  8/24/2017

• Infectious Disease Research Institute (IDRI) Receives $15 Million Commitment From Eli Lilly For TB Drug Discovery

  11/3/2016

• Infectious Disease Research Institute (IDRI) Receives FDA Grant To Develop RNA-Based Zika Virus Vaccine

  10/7/2016

• Infectious Disease Research Institute (IDRI) Adds Viral Vaccine Development Expertise; Expands Leadership

  4/13/2016

• Infectious Disease Research Institute (IDRI) And Sanofi Pasteur Team With Philanthropy To Develop New Model For Vaccine Development

  10/15/2015

• Infectious Disease Research Institute (IDRI) And Wellcome Trust Team For Tuberculosis Vaccine Trial In South Africa

  9/17/2015

• Amyris, Inc. And Infectious Disease Research Institute (IDRI) Announce Agreement To Explore Testing And Development Of Amyris Materials For Use In Vaccine Adjuvant Formulations

  9/9/2015

• Infectious Disease Research Institute (IDRI) Announces $4M Biomedical Advanced Research and Development Authority (BARDA) Cooperative Agreement To Establish Adjuvant Hub

  2/19/2015

• Infectious Disease Research Institute (IDRI) Announces $11.9M Contract To Develop Thermostable TB Vaccine

  11/20/2014

• Infectious Disease Research Institute (IDRI) Announces $11.9M Contract To Develop Thermostable TB Vaccine

  11/19/2014

• Infectious Disease Research Institute (IDRI) and Zydus Sign Agreement for Development of IDRI's Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar)

  7/25/2013

• Infectious Disease Research Institute (IDRI) and Medicago, Inc. Report Positive Results for Phase I Clinical Trial for an H5N1 Vaccine

  4/18/2013

• Infectious Disease Research Institute (IDRI) and Medicago, Inc. to Present Data at the World Vaccine Congress

  4/9/2013